Skip to main content
OpenTrials

Clinical trial condition

Multiple Myeloma

Explore clinical trials studying Multiple Myeloma. Study availability and eligibility vary by location and protocol.

2,610 public trials 494 recruiting studies
Refine in advanced search Browse all conditions

Multiple Myeloma trial results

Completed

A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)

NCT04196491

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Local Institution - 119 Phoenix, Arizona, United States
  • Local Institution - 110 Los Angeles, California, United States
  • Local Institution - 116 San Francisco, California, United States
  • Local Institution - 106 Denver, Colorado, United States
View all 22 locations
View Trial Details
Completed

A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

NCT02755597

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Rocky Mountain Regional VA Medical Center/Eastern Colorado Health Care System /ID# 156524 Aurora, Colorado, United States
  • Univ of Colorado Cancer Center /ID# 149130 Aurora, Colorado, United States
  • Duke Cancer Center /ID# 149099 Durham, North Carolina, United States
  • Gabrail Cancer Center Research /ID# 149098 Canton, Ohio, United States
View all 97 locations
View Trial Details
Completed

Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

NCT04445701

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Mayo Clinic Phoenix, Arizona, United States
  • Mayo Clinic Jacksonville, Florida, United States
  • Emory University Atlanta, Georgia, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details
Completed

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

NCT02034110

Conditions
Biliary Tract Diseases, Biliary Tract Neoplasms, Blood Protein Disorders, +35 more
Locations
  • Novartis Investigative Site Little Rock, Arkansas, United States
  • Novartis Investigative Site Santa Monica, California, United States
  • Novartis Investigative Site Bethesda, Maryland, United States
  • Novartis Investigative Site Boston, Massachusetts, United States
View all 41 locations
View Trial Details
Completed

A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide

NCT03215524

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Tom Baker Cancer Centre Calgary, Alberta, Canada
  • CrossCancer Institute Edmonton, Alberta, Canada
  • Fraser Valley Cancer Centre Surrey, British Columbia, Canada
  • CancerCare Manitoba Winnipeg, Manitoba, Canada
View Trial Details
Completed

A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma

NCT01145989

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Tom Baker Cancer Centre Calgary, Alberta, Canada
  • Cross Cancer Institute Edmonton, Alberta, Canada
  • Atlantic Health Sciences Corporation Saint John, New Brunswick, Canada
  • QEII Health Sciences Center Halifax, Nova Scotia, Canada
View Trial Details
Completed

Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma

NCT00305812

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Tom Baker Cancer Centre - Calgary Calgary, Alberta, Canada
  • Cross Cancer Institute at University of Alberta Edmonton, Alberta, Canada
  • British Columbia Cancer Agency - Centre for the Southern Interior Kelowna, British Columbia, Canada
  • Moncton Hospital Moncton, New Brunswick, Canada
View all 14 locations
View Trial Details
Completed

Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)

NCT01936532

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • CHRU - Hôpital du Haut Lévêque Bordeaux, France
  • CHRU Dijon Dijon, France
  • Centre hospitalier départemental Vendée La Roche-sur-Yon, France
  • CHRU - Hôpital Claude Huriez Lille, France
View Trial Details

Related conditions